Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Vistry confirms full-year outlook on buoyant demand

(Sharecast News) - Vistry Group reiterated its full-year outlook on Wednesday, after the house builder saw an improvement in its sales rate. Updating on trading ahead of its annual general meeting, Vistry said the sales rate in the year-to-date had increased since its last update in March, to 0.91 from 0.59.

In the last eight weeks, it averaged 1.32, comfortably above the average rate of 1.17 seen a year previously.

The housing market has seen a surge in demand in recent weeks, as buyers rushed to complete before changes to stamp duty thresholds came into effect in April.

However, Vistry said: "In the open market, we have seen an improvement in our sales rate over the past eight weeks, and we expect this trend to continue.

"Mortgage availability and affordability is improving, with lenders increasing their product range and borrowing rates reducing ahead of further expected cuts to the Bank of England base rate.

"We continue to expect full-year open market volumes to be at a similar level to 2024."

It concluded: "The group is making good progress and continues to expect to deliver a year-on-year increase in profits in the 2025 full-year with, as previously guided, a more significant second half weighting than in prior years."

Vistry's forward order book now totals £4.6bn, marginally down on last year's £4.9bn, with £2.1bn due for delivery this year.

As at 0915 BST, shares in Vistry were down nearly 3% at 616.78p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.